NFKB1 and multiple sclerosis: Dimethyl fumarate, an anti-inflammatory drug already used to treat multiple sclerosis and which potently inhibits NFκB signaling, effectively blocks human breast cancer cell growth in vitro and in vivo [80], while in chronic lymphocytic leukemia cells, the NFκB inhibitor, 6-Amino-4-(4-phenoxyphenethylamino)quinazoline, triggered apoptosis [81].